Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Iron Deficiency Anemia - Overview
Iron Deficiency Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Iron Deficiency Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iron Deficiency Anemia - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
Disc Medicine Inc
Entrinsic Bioscience Inc
Iron4u Aps
Jiangsu Aosaikang Pharmaceutical Co Ltd
Keros Therapeutics Inc
Nemysis Ltd
Novartis AG
Pharmacosmos AS
Renibus Therapeutics Inc
Rockwell Medical Inc
Shield Therapeutics Plc
Vifor Pharma Ltd
Iron Deficiency Anemia - Drug Profiles
AKB-5343 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CSJ-137 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DISC-0974 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Ferric bepectate - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
ferric derisomaltose - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric maltol - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric pyrophosphate citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
hinokitiol - Drug Profile
Product Description
Mechanism Of Action
IHAT-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
iron sucrose - Drug Profile
Product Description
Mechanism Of Action
History of Events
KER-047 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KTI-016 - Drug Profile
Product Description
Mechanism Of Action
KTI-018 - Drug Profile
Product Description
Mechanism Of Action
KTI-2338 - Drug Profile
Product Description
Mechanism Of Action
Monoclol Antibody 1 to Inhibit Hemojuvelin for Chronic Inflammation and Hematological Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
PT-30 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-007 - Drug Profile
Product Description
Mechanism Of Action
Iron Deficiency Anemia - Dormant Projects
Iron Deficiency Anemia - Discontinued Products
Iron Deficiency Anemia - Product Development Milestones
Featured News & Press Releases
Feb 04, 2022: Shield Therapeutics: Innovation in iron deficiency treatment with a focus on clinical utility of Accrufer/Feraccru
Dec 20, 2021: Vifor Pharma and American Regent announce settlement of Injectafer patent litigation
Dec 16, 2021: Shield Therapeutics: Patient access expands for Accrufer
Dec 16, 2021: Injectafer (ferric carboxymaltose injection) receives FDA approval for the treatment of pediatric patients with iron deficiency anemia
Dec 14, 2021: Rockwell Medical receives important feedback from FDA on its IND application for phase 2 trial of ferric pyrophosphate citrate in home infusion
Nov 16, 2021: Rockwell Medical study demonstrates no drug-drug interaction between ferric pyrophosphate citrate and unfractioted heparin
Nov 11, 2021: Rockwell Medical submits investigatiol new drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion
Nov 04, 2021: Rockwell Medical presents Triferic real world evidence update at ASN Kidney Week 2021
Aug 31, 2021: Vifor Pharma’s Ferinject granted new recommendations in updated 2021 ESC heart failure guidelines
Aug 09, 2021: Shield Therapeutics: AEGIS-CKD study results published in AJKD
Jun 28, 2021: Rockwell Medical files pre-IND meeting request with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion
Jun 24, 2021: Shield Therapeutics: US launch of Accrufer confirmed for July 1, 2021
May 21, 2021: Shield Therapeutics: US update
May 18, 2021: Shield Therapeutics: AEGIS-H2H study results published in Inflammatory Bowel Diseases
May 12, 2021: Nemysis announces grant of first Chinese patent for IHAT
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Iron Deficiency Anemia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Iron Deficiency Anemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Iron Deficiency Anemia - Pipeline by Akebia Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Disc Medicine Inc, 2022
Iron Deficiency Anemia - Pipeline by Entrinsic Bioscience Inc, 2022
Iron Deficiency Anemia - Pipeline by Iron4u Aps, 2022
Iron Deficiency Anemia - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022
Iron Deficiency Anemia - Pipeline by Keros Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Nemysis Ltd, 2022
Iron Deficiency Anemia - Pipeline by Novartis AG, 2022
Iron Deficiency Anemia - Pipeline by Pharmacosmos AS, 2022
Iron Deficiency Anemia - Pipeline by Renibus Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, 2022
Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, 2022
Iron Deficiency Anemia - Pipeline by Vifor Pharma Ltd, 2022
Iron Deficiency Anemia - Dormant Projects, 2022
Iron Deficiency Anemia - Discontinued Products, 2022